Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: EU-Poland

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: yes

    Payment Terms: L/C

    Ozanimod

    • Samples availability: 2025
    • OEB 4
    • Initial stage
    Status Pipeline
    Development phase Initial stage
    Therapeutic cat. Other
    CAS No. 1306760-87-1
    OEB No.

    4

    Samples 2025

    Drug description

    Ozanimod is used to treat relapsing forms of multiple sclerosis in adults (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease). Ozanimod is used only if you have a specific genotype. Ozanimod is also used to treat adults with moderately to severely active ulcerative colitis. It is not known if this medicine is safe and effective in children.

     

    Disclaimer: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).

Send your message to this supplier
  • From:
  • To:
    ZF Polpharma S.A.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service